Li ZhiYan, Han RuiLin, Yan ZhenLin, Li LiJuan, Feng ZhenRu
Department of Clinical Laboratory, Peking University First Hospital, Beijing, China.
J Clin Lab Anal. 2019 Jan;33(1):e22619. doi: 10.1002/jcla.22619. Epub 2018 Jul 20.
The indirect immunofluorescence assay (IIFA) for the detection of antinuclear antibodies (ANA) was firstly described in 1958 and is still considered the reference method for ANA screening. Currently, an automated processing and recognition system for standardized and efficient ANA interpretation by human epithelial (HEp-2) cell-based immunofluorescence (IIF; EUROPattern Suite, Euroimmun) is available in China.
In this study, the performance of this novel system for positive/negative classification, pattern recognition (including homogenous, speckled, nucleolar, nuclear dots, cytoplasmic, and centromeres patterns) and titers evaluation was evaluated by comparing to visual interpretation.
Referring to the total of 3681 collected samples, there was an agreement of 98.7% (κ = 0.973) between the visual and automated examination regarding positive/negative discrimination. In sera with single pattern, correct pattern recognition was observed in 94.6% of the samples. The efficiency of automated recognition for single pattern varied for the different patterns. The automatically determined patterns were correct and complete in 1071 of 1620 cases and correct and meaningful but not complete ("main pattern") in another 405 cases, enabling main pattern recognition in 91.1% of all cases. Referring to the titers evaluation, the results within the next titer were considered to be consistent. In 1603 positive sera both by visual and automated evaluation, titers of 1514 sample were consistent, accounting for 94.4%.
Attributed to the performance characteristics, EUROPattern system is suitable for clinical use as its high degree of automation and result reliability, and may help clinical laboratories to standardize of IIF evaluation.
间接免疫荧光法(IIFA)检测抗核抗体(ANA)于1958年首次被描述,至今仍被视为ANA筛查的参考方法。目前,中国已有一种基于人上皮(HEp-2)细胞免疫荧光法(IIF;EUROPattern套件,欧蒙公司)的用于标准化和高效解读ANA的自动化处理与识别系统。
在本研究中,通过与视觉判读相比较,评估了这种新型系统在阳性/阴性分类、模式识别(包括均质型、斑点型、核仁型、核点型、胞质型和着丝粒型模式)及滴度评估方面的性能。
在总共3681份采集样本中,视觉判读与自动化检测在阳性/阴性判别方面的一致性为98.7%(κ = 0.973)。在单一模式的血清样本中,94.6%的样本模式识别正确。单一模式的自动化识别效率因不同模式而异。在1620例病例中,自动判定的模式在1071例中正确且完整,在另外405例中正确且有意义但不完整(“主要模式”),使得91.1%的所有病例能够识别主要模式。在滴度评估方面,相邻滴度的结果被认为是一致的。在视觉和自动化评估均为阳性的1603份血清中,1514份样本的滴度一致,占94.4%。
鉴于其性能特点,EUROPattern系统自动化程度高且结果可靠,适用于临床应用,可能有助于临床实验室规范IIF评估。